Trial · NCT07185672
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
NCT07185672, Phase 3, Recruiting, Tata Memorial Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial). Trials, record NCT07185672. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07185672
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
- NCT number
- NCT07185672
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 162 participants, estimated
- Lead sponsor
- Tata Memorial Hospital
- Conditions
- Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic Tumour
- Interventions
- Peptide Receptor Radionuclide Therapy with Lu177 DOTATATE, Capecitabine plus temozolamide
- First posted
- 2025-09-22
- Last updated
- 2025-09-22
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival | From date of enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months | Progression-free survival (PFS) will be defined as the time from enrolment to the time of disease progression or death, or to the date of last tumor assessment (until 36 months from last day of completion of treatment) without any such event (censored observation). |
| Secondary | Overall survival | Time interval from enrolment to the date of death or last observation (censored), maximum until 24 months. | The duration of overall survival (OS) will be determined by measuring the time interval from enrolment to the date of death or last observation (censored). |
| Secondary | Quality of Life parameters | Day 1 of every treatment in both arms until treatment completion, and thereafter every 6 months upto 24 months | QOL analysis will be conducted using the following tools (with appropriate language translations) EORTC QLQ-30 EORTC G.I.NET-21 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07185672
GET https://conductscience.org/api/trials/v1/NCT07185672/registered